$300M MC will be very conservative given the massive revenue potential of both acute respiratory disease and chronic respiratory management for COPD and Asthma.
- Forums
- ASX - By Stock
- RAP
- Ann: Publication on challenges of diagnosing respiratory disease
Ann: Publication on challenges of diagnosing respiratory disease, page-25
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)